Taken together, our work identifies GSK-3β as a novel potential therapeutic target in RCC and suggests the combination of GSK-3 inhibitors and standard chemotherapy could be a superior treatment for human RCC. The gene discussed is GSK3B; the disease is renal cell adenocarcinoma.